Lupus is the feature of a new publication by the largest non-profit alliance committed to making medical research a national priority.
This week, LFA-supported researchers will share results of a study that could help expedite the delivery of new and safer therapies to people with lupus.
Aurinia Pharmaceuticals announced its plans for a single Phase III clinical trial for voclosporin in the treatment of lupus nephritis.
Trial results offer hope of a more effective and tolerable treatment option to manage lupus-related kidney disease.
Neuropsychiatric lupus mainly affects children and young adults and can weaken cognitive functions. With a new non-invasive imaging technique, the damage can now be studied.
New study results show that a short questionnaire designed for adolescents to assess the impact of lupus on quality of life makes it easier for them to report their mental, physical, and social well-being.
In some diseases, like lupus, sex-based differences may be the key to unlocking the mysteries and getting closer to treatments and cures.
Dr. Marshak-Rothstein will use the $200,000 award to advance her groundbreaking research into cutaneous lupus and autoimmunity.